MexBrain

MexBrain specializes in the development of advanced medical solutions for metal extraction and homeostasis restoration using a patented combination of dialysis and nanotechnology. The company targets healthcare providers and patients affected by metal toxicity due to genetic factors, environmental exposure, or aging. Operating within the medical technology sector, MexBrain's business model focuses on offering therapeutic solutions that enhance treatment efficiency. Revenue is generated through the commercialization of their proprietary product, MEX CD1, which utilizes ultrachelating compounds and biopolymers to effectively extract metals. The company has received funding through grants, such as the R&D Booster, to further develop its technology. MexBrain's approach addresses a critical need in the medical field, providing a novel solution to manage metal toxicity and improve patient outcomes.

Keywords: metal extraction, homeostasis, dialysis, nanotechnology, healthcare, toxicity, ultrachelating, biopolymer, therapeutic, MEX CD1.